0001209191-23-042454.txt : 20230717
0001209191-23-042454.hdr.sgml : 20230717
20230717170014
ACCESSION NUMBER: 0001209191-23-042454
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230714
FILED AS OF DATE: 20230717
DATE AS OF CHANGE: 20230717
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Curran Terrie
CENTRAL INDEX KEY: 0001690298
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39094
FILM NUMBER: 231092218
MAIL ADDRESS:
STREET 1: C/O MYOVANT SCIENCES INC.
STREET 2: 320 WEST 37TH STREET, 5TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001783183
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824151574
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (877) 742-8466
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-07-14
0
0001783183
Phathom Pharmaceuticals, Inc.
PHAT
0001690298
Curran Terrie
C/O PHATHOM PHARMACEUTICALS, INC.
100 CAMPUS DRIVE, SUITE 102
FLORHAM PARK
NJ
07932
1
1
0
0
President and Chief Executive
0
Common Stock
2023-07-14
4
A
0
200000
A
389671
D
Common Stock
3579.61
I
by 401(k)
Stock Option
32.20
2023-07-14
4
D
0
175000
D
2030-06-30
Common Stock
175000
0
D
Stock Option
39.11
2023-07-14
4
D
0
225000
D
2031-01-27
Common Stock
225000
0
D
On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock.
Includes 1,381 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023.
Includes 1,223.71 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.
/s/ Larry Miller, Attorney-in-Fact for Terrie Curran
2023-07-17